Last viewed:
TAK
Prices are updated after-hours
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
(0.0% 1d)
(-9.6% 1m)
(-21.0% 1y)
(0.0% 2d)
(0.0% 3d)
(-0.2% 7d)
(NaN%
volume)
Earnings Calendar:
Market Cap: $ 41,902,185,686
http://www.takeda.co.jp
Sec
Filling
|
Patents
| 47495 employees
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
diagnostics
qdenga
dengue
vaccine
add to watch list
Paper trade
email alert is off
Press-releases
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19
(Crawled : 02:00)
- prnewswire.com
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| 0.0%
| O: 0.42%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| 0.0%
| O: 0.82%
H: 0.0%
C: 0.0%
MIRM
|
News
|
$23.83
1.1%
1.09%
340K
|
Health Technology
| 0.0%
| O: 1.42%
H: 0.0%
C: 0.0%
report
million
reach
treatment
market
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18
(Crawled : 23:00)
- biospace.com/
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| 0.0%
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio
fda
disease
active
for
therapy
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15
(Crawled : 12:00)
- prnewswire.com
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -2.38%
| O: -1.19%
H: 0.26%
C: -0.98%
company
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26
(Crawled : 18:00)
- biospace.com/
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -7.07%
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma
japan
takeda
approval
injection
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19
(Crawled : 11:00)
- globenewswire.com
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -9.68%
| O: -0.07%
H: 0.0%
C: -0.96%
CNTG
|
$0.463
0.43%
0.43%
79K
|
Commercial Services
| -31.41%
| O: 1.43%
H: 1.41%
C: -1.41%
partnership
genetic
takeda
disorders
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19
(Crawled : 17:00)
- biospace.com/
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -9.68%
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig
fda
drug
takeda
approval
application
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15
(Crawled : 14:30)
- prnewswire.com
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -8.3%
| O: 0.21%
H: 0.97%
C: 0.7%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| -5.15%
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
| -9.85%
| O: -1.58%
H: 0.0%
C: 0.0%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
| -1.31%
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -8.4%
| O: -0.07%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -6.03%
| O: -0.02%
H: 0.0%
C: 0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
| -6.03%
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
| -2.43%
| O: 0.2%
H: 1.14%
C: -1.18%
antibody
therapeutics
market
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13
(Crawled : 13:30)
- biospace.com/
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -8.49%
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079
positive
topline
potential
results
study
Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04
(Crawled : 12:00)
- prnewswire.com
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -9.68%
| O: -0.69%
H: 0.35%
C: 0.14%
ARE
A
|
$115.69
-0.7%
0.0%
940K
|
Finance
| -5.86%
| O: -0.01%
H: 1.98%
C: 1.41%
extension
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27
(Crawled : 09:00)
- biospace.com/
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
| -11.21%
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine
dengue
tak-003
qdenga
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount